Apogee Therapeutics, Inc. Common Stock Asset Resilience Ratio
Apogee Therapeutics, Inc. Common Stock asset resilience ratio. Apogee Therapeutics, Inc. Common Stock (APGE) has an Asset Resilience Ratio of 64.86% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See APGE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Apogee Therapeutics, Inc. Common Stock (2022–2025)
Asset resilience ratio of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. This chart shows how Apogee Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read total liabilities of Apogee Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Apogee Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Apogee Therapeutics, Inc. Common Stock total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $866.36 Million | 64.86% |
| Total Liquid Assets | $866.36 Million | 64.86% |
Asset Resilience Insights
- Very High Liquidity: Apogee Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 64.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Apogee Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Apogee Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Apogee Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2022–2025)
Apogee Therapeutics, Inc. Common Stock asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Apogee Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.88% | $598.64 Million | $937.13 Million | +13.63pp |
| 2024-12-31 | 50.25% | $378.86 Million | $753.95 Million | -18.79pp |
| 2023-12-31 | 69.04% | $277.14 Million | $401.40 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $152.06 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chr… Read more